Objective To investigate the factors associated with HIV1 RNA plasma viral load (pVL) below 40 copies/mL at the third trimester of pregnancy, as part of prevention of mother-to-child transmission (PMTCT) in Benin. Design Sub study of the PACOME clinical trial of malaria prophylaxis in HIV-infected pregnant women, conducted before and after the implementation of the WHO 2009 revised guidelines for PMTCT. Methods HIV-infected women were enrolled in the second trimester of pregnancy. Socio-economic characteristics, HIV history, clinical and biological characteristics were recorded. Malaria prevention and PMTCT involving antiretroviral therapy (ART) for mothers and infants were provided. Logistic regression helped identifying factors associated with virologic suppression at the end of pregnancy. Results Overall 217 third trimester pVLs were available, and 71% showed undetectability. Virologic suppression was more frequent in women enrolled after the change in PMTCT recommendations, advising to start ART at 14 weeks instead of 28 weeks of pregnancy. In multivariate analysis, Fon ethnic group (the predominant ethnic group in the study area), regular job, first and second pregnancy, higher baseline pVL and impaired adherence to ART were negative factors whereas higher weight, higher antenatal care attendance and longer ART duration were favorable factors to achieve virologic suppression. Conclusions This study provides more evidence that ART has to be initiated before the last trimester of pregnancy to achieve an undetectable pVL before delivery. In Benin, new recommendations supporting early initiation were well implemented and, together with a high antenatal care attendance, led to high rate of virologic control.
References
[1]
UNAIDS (2012) UNAIDS report on the global AIDS epidemic |. 2012: UNAIDS/JC2417E.
[2]
Brahmbhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Lutalo T, et al. (2006) Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr 41: 504–508.
[3]
De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, et al. (2000) Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 283: 1175–1182.
[4]
Zijenah LS, Moulton LH, Iliff P, Nathoo K, Munjoma MW, et al. (2004) Timing of mother-to-child transmission of HIV-1 and infant mortality in the first 6 months of life in Harare, Zimbabwe. AIDS 18: 273–280.
[5]
Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, et al. (2002) Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29: 484–494.
[6]
Becquet R, Ekouevi DK (2011) Breastfeeding, triple ARV prophylaxis, and MTCT prevention. Lancet Infect Dis 11: 154–155.
[7]
Kesho Bora Study Group, de Vincenzi I (2011) Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 11: 171–180.
[8]
WHO (2010) Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access (2010 version). Geneva, Switzerland: World Health Organization. Available: http://www.who.int/hiv/pub/mtct/antiretr？oviral2010/en/index.html. Accessed July 2010.
[9]
Fawzi W, Msamanga G, Renjifo B, Spiegelman D, Urassa E, et al. (2001) Predictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women. AIDS 15: 1157–1165.
[10]
Jourdain G, Mary JY, Coeur SL, Ngo-Giang-Huong N, Yuthavisuthi P, et al. (2007) Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. J Infect Dis 196: 1629–1636.
[11]
Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, et al (1999) Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 341: 385–393.
[12]
Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM (1999) Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African Vitamin A Study Group. Lancet 354: 471–476.
[13]
Cowan FM, Humphrey JH, Ntozini R, Mutasa K, Morrow R, et al. (2008) Maternal Herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. AIDS 22: 193–201.
[14]
Denoeud-Ndam L, Clement MC, Briand V, Akakpo J, Agossou VK, et al. (2012) Tolerability of mefloquine intermittent preventive treatment for malaria in HIV-infected pregnant women in Benin. J Acquir Immune Defic Syndr 61: 64–72.
[15]
Arman M, Raza A, Tempest LJ, Lyke KE, Thera MA, et al. (2007) Platelet-mediated clumping of Plasmodium falciparum infected erythrocytes is associated with high parasitemia but not severe clinical manifestations of malaria in African children. Am J Trop Med Hyg 77: 943–946.
[16]
Kahn JG, Muraguri N, Harris B, Lugada E, Clasen T, et al. (2012) Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness. PLoS One 7: e31316.
[17]
Katz IT, Shapiro R, Li D, Govindarajulu U, Thompson B, et al. (2010) Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study. J Acquir Immune Defic Syndr 54: 27–34.
[18]
European Collaborative Study, Patel D, Cortina-Borja M, Thorne C, Newell ML (2007) Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 44: 1647–1656.
[19]
Read PJ, Mandalia S, Khan P, Harrisson U, Naftalin C, et al. (2012) When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS 26: 1095–1103.
[20]
Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, et al. (2010) Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 362: 2282–2294.
[21]
Chibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, et al. (2011) Optimal time on HAART for prevention of mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 58: 224–228.
[22]
Hoffman RM, Black V, Technau K, van der Merwe KJ, Currier J, et al. (2010) Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr 54: 35–41.
[23]
Izzo I, Forleo MA, Casari S, Quiros-Roldan E, Magoni M, et al. (2011) Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). BMC Public Health 11: 124.
[24]
Marazzi MC, Liotta G, Nielsen-Saines K, Haswell J, Magid NA, et al. (2010) Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life. AIDS 24: 2819–2826.
[25]
WHO (2012) Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Programmatic update. Geneva, Switzerland. Available: http://www.who.int/hiv/pub/mtct/programm？atic_update2012/en/index.html. Accessed April 2012.
[26]
Denoeud L, Fievet N, Aubouy A, Ayemonna P, Kiniffo R, et al. (2007) Is chloroquine chemoprophylaxis still effective to prevent low birth weight? Results of a study in Benin. Malar J 6: 27.
[27]
Huynh BT, Fievet N, Gbaguidi G, Dechavanne S, Borgella S, et al. (2011) Influence of the timing of malaria infection during pregnancy on birth weight and on maternal anemia in Benin. Am J Trop Med Hyg 85: 214–220.
[28]
Duri K, Gumbo FZ, Kristiansen KI, Kurewa NE, Mapingure MP, et al. (2010) Antenatal HIV-1 RNA load and timing of mother to child transmission; a nested case-control study in a resource poor setting. Virol J 7: 176.
[29]
El-Khatib Z, Ekstrom AM, Coovadia A, Abrams EJ, Petzold M, et al. (2011) Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa – a prospective cohort study. BMC Public Health 11: 88.
[30]
Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, et al. (2008) Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 24: 1263–1268.
[31]
Brahmbhatt H, Sullivan D, Kigozi G, Askin F, Wabwire-Mangenm F, et al. (2008) Association of HIV and malaria with mother-to-child transmission, birth outcomes, and child mortality. J Acquir Immune Defic Syndr 47: 472–476.
[32]
Kapiga SH, Bang H, Spiegelman D, Msamanga GI, Coley J, et al. (2002) Correlates of plasma HIV-1 RNA viral load among HIV-1-seropositive women in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 30: 316–323.
[33]
Mwapasa V, Rogerson SJ, Molyneux ME, Abrams ET, Kamwendo DD, et al. (2004) The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS 18: 1051–1059.
[34]
Roberts T, Bygrave H, Fajardo E, Ford N (2012) Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc 15: 17324.
